{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+methylprednisolone+%28steroids%29&page=3", "query": { "intervention": "IV methylprednisolone (steroids)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 240, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+methylprednisolone+%28steroids%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+methylprednisolone+%28steroids%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T13:29:09.752Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04305145", "title": "Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Skin Cancer Stage III", "Skin Cancer Stage IV", "Drug-Induced Colitis", "Drug Toxicity", "Immune-related Adverse Event" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-08-31", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305145" }, { "nct_id": "NCT04544436", "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 864, "start_date": "2020-11-26", "completion_date": "2028-02-21", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 25, "location_summary": "Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544436" }, { "nct_id": "NCT00568633", "title": "Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myeloid", "Leukemia", "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Cyclosporine (CSP)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Total lymphoid irradiation (TLI)", "type": "RADIATION" }, { "name": "Methylprednisolone sodium succinate", "type": "DRUG" }, { "name": "Best standard care", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 58, "start_date": "2007-08", "completion_date": "2015-12-31", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 5, "location_summary": "Hayward, California • Los Angeles, California • Sacramento, California + 2 more", "locations": [ { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00568633" }, { "nct_id": "NCT03407144", "title": "Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone/prednisolone", "type": "DRUG" }, { "name": "bleomycin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "Radiotherapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "3 Years to 25 Years" }, "enrollment_count": 340, "start_date": "2018-04-09", "completion_date": "2027-02-12", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407144" }, { "nct_id": "NCT00002565", "title": "Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "CHOP regimen", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 61, "start_date": "1994-05-25", "completion_date": "2007-02-05", "has_results": false, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002565" }, { "nct_id": "NCT01105650", "title": "Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "Breast Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Natural killer cells", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2010-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105650" }, { "nct_id": "NCT00002718", "title": "T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 31, "start_date": "1995-11", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2015-12-23", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002718" }, { "nct_id": "NCT00186628", "title": "Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Mast-Cell", "Mantle-cell Lymphoma" ], "interventions": [ { "name": "Total lymphoid irradiation", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Anti-thymoglobulin, rabbit (ATG, rabbit ATG)", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenylate mofetil", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 36, "start_date": "2005-06", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186628" }, { "nct_id": "NCT04408625", "title": "Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Frontotemporal Dementia" ], "interventions": [ { "name": "LY3884963", "type": "BIOLOGICAL" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Optional Sirolimus", "type": "DRUG" }, { "name": "Optional Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Prevail Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 35, "start_date": "2020-11-09", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 4, "location_summary": "Maitland, Florida • Orlando, Florida • Burlington, Massachusetts + 1 more", "locations": [ { "city": "Maitland", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04408625" }, { "nct_id": "NCT01496976", "title": "Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "High Dose Methylprednisolone (HDMP)", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-03-30", "completion_date": "2024-09-11", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-11T13:29:09.752Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496976" } ] }